Abstract
Stable ischaemic heart disease is a frequent and very heterogeneous condition. Drug therapy is important, in these patients, for improving their prognosis and controlling their symptoms. The typical clinical manifestation of obstructive coronary disease is angina pectoris. This symptom can be improved by various classes of compounds, namely beta-blockers (BBs), calcium antagonist, and nitrates. More recently, ranolazine and ivabradine have been introduced. All these drugs have been proven to reduce significantly angina. On the other hand, there are no evidences supporting improvement in prognosis, besides for the use of BBs, in patients with previous myocardial infarction (MI) or systolic dysfunction. Besides drugs for symptoms control, these patients also receive antiplatelet drugs, specifically aspirin, and lipid lowering compounds such as statins. Furthermore, recent evidences supported the use of low doses direct anticoagulant, or a second antiplatelet agent in patients with previous MI. Similarly, a very low LDL cholesterol level, such as obtained with PCKS9 inhibitors, seems very beneficial in these patients. It is possible that in the near future a specific role for neo-angiogenesis factors and cellular therapies, could ...Continue Reading
References
Mar 1, 1987·Journal of the American College of Cardiology·R S KohliE B Raftery
Aug 1, 1994·Circulation·C J PepineU Thadani
Jan 1, 1996·European Heart Journal·N RehnqvistN H Wallén
Jan 1, 1996·European Heart Journal·K M FoxH J Dargie
Jun 25, 1999·BMJ : British Medical Journal·N FreemantleJ Harrison
Jan 22, 2004·JAMA : the Journal of the American Medical Association·Bernard R ChaitmanUNKNOWN Combination Assessment of Ranolazine In Stable Angina (CARISA) Investigators
Apr 20, 2004·Journal of the American College of Cardiology·Bernard R ChaitmanUNKNOWN MARISA Investigators
Sep 8, 2004·Lancet·Philip A Poole-WilsonUNKNOWN Coronary disease Trial Investigating Outcome with Nifedipine gastrointestinal therapeutic system investigators
Sep 24, 2005·European Heart Journal·Adam D TimmisMichael Crager
May 24, 2006·Circulation·Bernard R Chaitman
Aug 1, 2006·Journal of the American College of Cardiology·Peter H StoneUNKNOWN ERICA Investigators
Apr 26, 2007·JAMA : the Journal of the American Medical Association·David A MorrowUNKNOWN MERLIN-TIMI 36 Trial Investigators
Sep 2, 2008·Lancet·Kim FoxUNKNOWN BEAUTIFUL Investigators
Apr 1, 2009·The American Journal of Medicine·Sripal BangaloreFranz H Messerli
Apr 25, 2009·Journal of the American College of Cardiology·Sean R WilsonDavid A Morrow
Jun 12, 2010·Cardiology in Review·Vaughn E NossamanPhilip J Kadowitz
Jun 19, 2010·International Journal of Cardiology·Jiafu WeiDejia Huang
Nov 3, 2011·Archives of Cardiovascular Diseases·Jean-Louis GayetAlain Cohen-Solal
Jul 11, 2012·European Journal of Preventive Cardiology·De Fen ShuGuan Jian Liu
Oct 4, 2012·JAMA : the Journal of the American Medical Association·Sripal BangaloreUNKNOWN REACH Registry Investigators
Nov 28, 2012·Journal of the American College of Cardiology·Stephan D FihnUNKNOWN Society of Thoracic Surgeons
Mar 12, 2013·Clinical Medicine : Journal of the Royal College of Physicians of London·Jason M Tarkin, Juan Carlos Kaski
Sep 3, 2013·European Heart Journal·UNKNOWN Task Force MembersJose Luis Zamorano
Jun 21, 2014·Heart·Christophe BautersNicolas Lamblin
Sep 2, 2014·The New England Journal of Medicine·Kim FoxUNKNOWN SIGNIFY Investigators
Oct 2, 2014·Circulation. Cardiovascular Quality and Outcomes·Sripal BangaloreA Michael Lincoff
Mar 17, 2015·The New England Journal of Medicine·Marc P BonacaUNKNOWN PEGASUS-TIMI 54 Steering Committee and Investigators
Oct 18, 2015·Lancet·Giora WeiszUNKNOWN RIVER-PCI investigators
Jan 13, 2016·Current Atherosclerosis Reports·Joseph Walker KeachThomas M Maddox
Aug 6, 2016·JACC. Cardiovascular Interventions·Thomas J PovsicUNKNOWN RENEW Investigators
Aug 9, 2016·Annals of Translational Medicine·Fabian Sanchis-GomarAlejandro Lucia
Mar 18, 2017·The New England Journal of Medicine·Marc S SabatineUNKNOWN FOURIER Steering Committee and Investigators
Apr 1, 2017·Journal of Cardiovascular Pharmacology and Therapeutics·Santosh K PadalaPeter P Toth
Aug 29, 2017·The New England Journal of Medicine·Paul M RidkerUNKNOWN CANTOS Trial Group
Nov 6, 2017·Current Atherosclerosis Reports·Rahul R GoliJay Giri
Nov 15, 2017·Lancet·Stuart J ConnollyUNKNOWN COMPASS investigators
Dec 23, 2017·Rheumatology·Pascal RichetteThomas Bardin
Jul 24, 2018·Cardiovascular Therapeutics·Rong YuanKeji Chen